Advertisement

Topics

The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

2016-01-21 15:15:46 | BioPortfolio

Published on BioPortfolio: 2016-01-21T15:15:46-0500

Clinical Trials [3721 Associated Clinical Trials listed on BioPortfolio]

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

The study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among ca...

Low Molecular Weight Heparin in Recurrent Implantation Failure

Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments...

Heparin Antibodies in Intensive Care Unit Patients (HAICU)

Intensive care unit patients have multiple risk factors for venous thromboembolism. Venous thromboembolism leads to significant morbidity and can be fatal. Unfractionated heparin and low...

OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis

A randomised, prospective, cross over study will be done to determine whether the anticoagulation therapy with UFH or LMWH used for hemodialysis sessions modifies osteoprotegerin and RANKL...

Heparin Induced Thrombocytopenia: Pharmacoeconomics

Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the...

PubMed Articles [18381 Associated PubMed Articles listed on BioPortfolio]

Molecular dynamics-based model of VEGF-A and its heparin interactions.

We present a computational model of the Vascular Endothelial Growth Factor (VEGF), an important regulator of blood vessels formation, which function is affected by its heparin interactions. Although s...

Feasibility of an estimated method using graduated utensils to estimate food portion size in infants aged 4 to 18 months.

The Diet and Nutrition Survey of Infants and Young Children (DNSIYC) was carried out in 2011 to assess the nutrient intakes of 4 to 18 month old infants in the UK. Prior to the main stage of DNSIYC, p...

Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention.

It remains unknown if bivalirudin compared to heparin confers any additional inhibition of platelet and coagulation activation during primary percutaneous coronary intervention (PPCI) after pretreatme...

Low molecular weight heparin treatment of acute moderate and severe pancreatitis: A randomized, controlled, open-label study.

Acute pancreatitis (AP) runs a moderately severe and severe course in 20%-30% of cases. The purpose of the present study was to determine the effect of low molecular weight heparin (LMWH) for the prev...

Is Activation of Human Brown Adipose Tissue a Viable Target for Weight Management?

To date, human studies show that BAT contributes a small, yet highly variable amount to overall energy expenditure. No studies have shown a decrease in body weight with cold-induced BAT activation, an...

Medical and Biotech [MESH] Definitions

Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.

A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed)

Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)

A medical device used to ensure the proper amount of medication is delivered for inhalation. Usually, it is a small aerosol canister placed in a plastic holder. When the canister is pressed, a calibrated amount of drug is released.

More From BioPortfolio on "The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial